Today: 20 May 2026
Browse Category

NYSE:HUM 15 October 2025 - 28 January 2026

Dow Jones flattens near 49,000 as S&P 500 hits 7,000; Fed and Big Tech earnings loom

Dow Jones flattens near 49,000 as S&P 500 hits 7,000; Fed and Big Tech earnings loom

The Dow rose 49.62 points to 49,053.03 by midday Wednesday as the S&P 500 briefly topped 7,000 before retreating. Intel jumped 11.3%, while UnitedHealth plunged nearly 20% after the Trump administration proposed a 0.09% Medicare Advantage rate hike for 2027. The Fed is expected to hold rates steady. Seagate surged 19.3% on earnings.
28 January 2026
·······
Dow Jones today: Dow hovers near 49,000 as Fed decision and mega-cap earnings loom

Dow Jones today: Dow hovers near 49,000 as Fed decision and mega-cap earnings loom

The Dow Jones hovered near 49,000 Wednesday morning, dipping 3.56 points to 48,999.85 as UnitedHealth’s sharp fall continued to weigh on the index. The S&P 500 briefly topped 7,000, boosted by chip stocks after upbeat results from ASML and SK Hynix. The Federal Reserve’s policy decision is due at 2 p.m. EST. Meta, Microsoft, Tesla, and IBM report earnings after the bell.
28 January 2026
···········
Dow Jones today: Dow futures inch up as Fed decision and Big Tech earnings loom

Dow Jones today: Dow futures inch up as Fed decision and Big Tech earnings loom

Dow futures rose about 30 points ahead of the Fed’s policy decision, with S&P 500 and Nasdaq 100 futures also up. Health insurers slumped after U.S. officials proposed a 0.09% Medicare Advantage payment hike, far below expectations. The Dow fell 409 points Tuesday, dragged by UnitedHealth, Humana, and CVS losses, while the S&P 500 and Nasdaq hit records on tech gains. Microsoft and Meta will report earnings Wednesday.
28 January 2026
·····
Humana stock price tumbles 21% after Medicare Advantage rate proposal — what to watch next

Humana stock price tumbles 21% after Medicare Advantage rate proposal — what to watch next

Humana shares fell 21.1% to $207.93 in after-hours trading Tuesday after the Centers for Medicare & Medicaid Services proposed a 0.09% average payment increase for Medicare Advantage in 2027, far below analyst expectations. The draft also included stricter rules on diagnosis data. U.S. health insurer stocks dropped sharply, erasing billions in market value. Comments on the proposal are due by Feb. 25.
28 January 2026
··
UnitedHealth Group stock price tumbles: UNH slides nearly 20% after outlook, Medicare Advantage rates in focus

UnitedHealth Group stock price tumbles: UNH slides nearly 20% after outlook, Medicare Advantage rates in focus

UnitedHealth Group shares fell 19.5% to $282.90 in after-hours trading Tuesday after a weak Medicare Advantage rate proposal from the Trump administration. The company expects to lose up to 1.4 million Medicare Advantage members in 2026 and forecasts a drop in Medicaid membership. CVS and Humana shares also plunged. The government’s final Medicare Advantage rate decision is due April 6.
27 January 2026
···
UnitedHealth stock tumbles nearly 20% as Medicare Advantage rate proposal rattles UNH investors

UnitedHealth stock tumbles nearly 20% as Medicare Advantage rate proposal rattles UNH investors

UnitedHealth shares fell 18.4% to $286.96 Tuesday after a U.S. proposal signaled Medicare Advantage payments would rise just 0.09% in 2027. The company warned of its first revenue drop since 1989 despite maintaining its 2026 profit outlook. CVS Health and Humana also posted sharp declines. CMS will accept comments on the proposed rates through Feb. 25.
27 January 2026
···
Dow Jones drops 450 points as UnitedHealth sinks on Medicare rates; confidence slumps

Dow Jones drops 450 points as UnitedHealth sinks on Medicare rates; confidence slumps

The Dow Jones fell 445 points, or 0.9%, to 48,966 in early trading, dragged down by a 20% plunge in UnitedHealth after weak Medicare payment proposals and a downbeat 2026 forecast. U.S. consumer confidence dropped to its lowest since 2014. The S&P 500 and Nasdaq rose, while Humana and CVS also tumbled. Traders watched for earnings and the Fed meeting starting Tuesday.
27 January 2026
···
Why UnitedHealth stock fell today: UNH slides as Medicare Advantage spotlight returns

Why UnitedHealth stock fell today: UNH slides as Medicare Advantage spotlight returns

UnitedHealth shares fell 2.3% to $331.02 in after-hours trading Friday following a MedPAC report highlighting $76 billion in projected Medicare Advantage overpayments. The drop came ahead of a long holiday weekend and the company’s earnings release set for Jan. 27. Managed-care stocks broadly declined, with Humana down 3.76% and Elevance Health off 1.85%.
17 January 2026
···
UnitedHealth stock drops today — what traders are watching before UNH earnings

UnitedHealth stock drops today — what traders are watching before UNH earnings

UnitedHealth shares fell 1.3% to $334.40 Friday, weighing on the Dow as managed-care stocks slid after Trump’s new healthcare proposal. The plan, which would replace insurance subsidies with direct payments to consumers, left policy details unclear and insurers under pressure. UnitedHealth will report 2025 earnings and its 2026 outlook on Jan. 27. Investors are watching for updates on government-plan costs and future guidance.
16 January 2026
······
UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings

UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings

UnitedHealth shares fell over 2% to $340.44 Wednesday morning, erasing part of Tuesday’s gain. The drop followed analyst moves, with Bernstein raising its target to $444 and Evercore ISI starting coverage at $400. Investors await UnitedHealth’s Jan. 27 results and Medicare Advantage rate updates. Humana and Cigna also declined.
7 January 2026
·······
UnitedHealth stock ticks up after Barclays target hike as UNH earnings near

UnitedHealth stock ticks up after Barclays target hike as UNH earnings near

UnitedHealth shares rose 0.8% to $338.94 in late-morning trading Monday after Barclays raised its price target to $391 and reiterated an Overweight rating. Investors are watching ahead of Jan. 27, when UnitedHealth will report 2025 results and 2026 guidance. Scrutiny remains on medical-cost trends, operational review progress, and ongoing Justice Department investigations into Medicare Advantage billing.
5 January 2026
·····
UnitedHealth stock rises into the weekend — what UNH investors watch before Jan. 27 results

UnitedHealth stock rises into the weekend — what UNH investors watch before Jan. 27 results

UnitedHealth Group shares rose 1.9% to $336.40 Friday, trading 6.9 million shares and closing above key moving averages. The company will report full-year results and its 2026 outlook before the market opens Jan. 27. UnitedHealth remains under Justice Department investigation over billing practices. The stock is well below its 52-week high of $606.36.
5 January 2026
····
UnitedHealth Group (UNH) Stock After Hours Today (Dec. 15, 2025): Key News, Analyst Forecasts, and What to Watch Before Tuesday’s Open

UnitedHealth Group (UNH) Stock After Hours Today (Dec. 15, 2025): Key News, Analyst Forecasts, and What to Watch Before Tuesday’s Open

UnitedHealth (UNH) closed Monday down 0.22% at $341.10 and slipped to $340.14 after hours. The move followed Fitch’s downgrade of rival Humana, citing higher medical costs and weaker Medicare Advantage bonuses. UNH traded 6.3 million shares in a $337–$344.96 range. Industry commentary remains focused on rising expenses and regulatory pressure.
16 December 2025
···
Humana Stock (HUM) Outlook December 4, 2025: Earnings Beat, Legal Risks and 2026 Medicare Advantage Forecast

Humana Stock (HUM) Outlook December 4, 2025: Earnings Beat, Legal Risks and 2026 Medicare Advantage Forecast

Humana shares traded in the mid-$250s on December 4, down 12% over the past year and 18% below their September high. The stock is up just 1.3% year to date, lagging the SPDR S&P Health Care Services ETF’s nearly 20% gain. Institutional investors, including Norges Bank, increased stakes in 2025, with about 92% of shares now institutionally held. Regulatory headlines and guidance changes have driven sharp price swings.
4 December 2025
··
Humana (HUM) Stock on Nov 5, 2025: Earnings Beat, Outlook Trimmed – Full Analysis

Humana (HUM) Stock on Nov 5, 2025: Earnings Beat, Outlook Trimmed – Full Analysis

Humana shares traded at $269 on Nov 5, 2025, after Q3 earnings beat expectations with adjusted EPS of $3.24 and revenue of $32.65 billion. The company reaffirmed full-year adjusted EPS guidance but cut its GAAP forecast due to higher medical costs. Shares fell 4% pre-market. Humana projects a 7% drop in Medicare Advantage membership for 2025 after a major plan’s star rating downgrade.
5 November 2025
··
Humana Hit Hard: Judge Upholds Medicare Advantage Star Cut, Stock Slides

Humana Hit Hard: Judge Upholds Medicare Advantage Star Cut, Stock Slides

A federal judge on Oct. 14 upheld the U.S. government’s downgrade of Humana’s 2025 Medicare Advantage star rating from 4.5 to 3.5 stars, dismissing Humana’s lawsuit. The ruling leaves about 45% of Humana’s Medicare Advantage members in lower-rated plans and could cost the company an estimated $1 billion in lost federal bonus payments next year. Humana shares fell 3–4% on the news. The company said it may appeal.
15 October 2025
·
1 2 3

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Go toTop